Beyond MRD Negative: FORTE Trial Reveals Why Staying MRD Negative Matters in Myeloma | ASCO 2026

Minimal residual disease (MRD) negativity has become one of the most important goals in multiple myeloma treatment—but is achieving MRD negativity enough?
In this video, we explore new findings from the FORTE trial presented at ASCO 2026, showing that the duration and sustainability of MRD negativity may be just as important as achieving it in the first place. Researchers examined how sustained MRD-negative status correlates with long-term outcomes, including progression-free survival, and what these findings could mean for treatment decisions and patient monitoring.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.